Last updated 9 August 2026 · Originally published 8 October 2021
Arthritis is one of the most common reasons people try CBD. An Arthritis Foundation survey of around 2,600 people found 29% were already using it, and another third were interested.[11]
The research has caught up somewhat since then, and the picture is more specific than “does CBD work for arthritis?” The evidence differs by the type of arthritis, and by whether CBD is swallowed or applied to the skin.
Why it seemed promising
The animal work is genuinely encouraging, and it’s where most of the enthusiasm comes from.
A 2017 study found that local administration of CBD blocked osteoarthritis pain in rats and prevented the nerve damage that develops later.[1] An earlier study applying CBD gel to rats’ skin reported long-lasting reductions in inflammation and pain behaviour.[2]
Arthritis is also, in many forms, an inflammatory disease — and CBD’s anti-inflammatory activity in the laboratory is well established. So the reasoning isn’t fanciful.
What happened when it was tested in people
Mostly disappointment, although the small topical studies are more encouraging.
Taken by mouth: no clear benefit so far
Three controlled trials have now tested oral CBD or CBD-rich oil in arthritis, at doses ranging from ordinary retail territory to far above it.
In 2023, researchers in Vienna gave 86 people with painful knee osteoarthritis either 600 mg of CBD daily or placebo alongside paracetamol for eight weeks. CBD did not improve pain, stiffness, function or quality of life — and adverse effects were significantly more common, including rises in liver enzymes.[3]
A trial in 136 people with hand osteoarthritis or psoriatic arthritis tested 20–30 mg of synthetic CBD daily for twelve weeks. Again, no significant difference in pain intensity.[4]
The most recent trial randomised 45 people with knee osteoarthritis to a CBD-rich oil delivering 45 mg daily, or placebo, for two months. Both groups improved — but CBD produced no additional benefit for pain, sleep, mood or quality of life.[5] The oil was described as full-spectrum, though its THC and minor cannabinoids were below the laboratory’s detection limit.
Low dose, moderate dose and high dose. None has yet beaten placebo for oral treatment of arthritis.
Applied through the skin: maybe
This is where it gets more interesting.
A randomised controlled trial of topical CBD for thumb basal joint arthritis — 18 people, two weeks — reported improvements in pain and disability.[6] Small, but a positive randomised result.
An open-label study tested an engineered transdermal CBD gel in people with hand osteoarthritis. Fifteen participants completed four weeks, during which pain fell by around two points and grip strength improved. Some of those changes drifted back towards baseline after treatment stopped.[7]
Encouraging — but everyone knew they were receiving CBD, and there was no placebo group. The authors called it a feasibility study and said efficacy needs a randomised controlled trial.
Why the split might make sense
Local delivery is an appealing explanation, but it hasn’t been demonstrated. Applying CBD over a painful joint avoids the losses involved in swallowing it — though skin is itself a formidable barrier. The transdermal hand study used a specialised penetration enhancer, so its results can’t be transferred to an ordinary CBD cream. For now the oral-versus-topical split is an interesting pattern, not proof that topical CBD reaches the joint.
What about rheumatoid arthritis?
Much less studied, and worth separating from osteoarthritis because the diseases are different.
Rheumatoid arthritis is autoimmune: the immune system attacks the joints, and untreated it causes permanent joint damage. That makes it a condition where delaying proper treatment has consequences you can’t undo.
Modern RA treatment — disease-modifying drugs and biologics — doesn’t just relieve symptoms, it slows the disease. No human evidence shows that CBD does that, or protects joints from damage.
If you have RA, CBD is something to discuss with your rheumatologist as an addition. It is not a substitute for treatment that protects your joints.
Does whole-plant cannabis do better?
Reasonable question, given that for many kinds of pain the evidence favours THC-containing products over CBD alone. Our guide to CBD for pain goes through that.
For arthritis specifically, the answer is less clear-cut. One systematic review found cannabinoids outperformed placebo in neuropathic pain but not in pain from rheumatic diseases — so the THC advantage doesn’t obviously transfer to arthritic joints.[8]
There is some supportive evidence. A trial of a THC–CBD spray in 58 people with rheumatoid arthritis found small improvements in pain, sleep and a disease-activity score after five weeks.[9]
A 2024 scoping review found six of ten included studies reported significant pain improvement.[10] But those ten comprised only four randomised trials alongside surveys, case reports and a cohort study. The reviewers concluded the evidence remained insufficient for recommendations.
Animal studies have raised the possibility that cannabinoids might influence inflammatory activity and joint damage rather than only pain — the rat osteoarthritis work found CBD prevented the nerve damage that develops later, not just the pain.[1] That’s genuinely interesting because it suggests an effect beyond short-term pain behaviour. But it doesn’t show that CBD slows arthritis or protects human joints, and it’s no basis for replacing disease-modifying treatment.
None of it amounts to established treatment. Cannabis isn’t a routinely recommended treatment for rheumatic disease, and rheumatology bodies have generally held back for want of good trials.
What people report
The trials aren’t the only evidence worth weighing. In the Arthritis Foundation survey, most current users reported some improvement in pain, stiffness or sleep.[11] Other surveys have found similar patterns.
Those experiences deserve attention, but they can’t establish cause. Arthritis fluctuates, expectation matters, and most people use CBD alongside other treatments. What the trials may be missing is whether a particular group experiences broader benefits across pain, stiffness, sleep and daily function — and how you’d identify that group in advance.
If you want to try it
For a specific painful joint, a topical is the more defensible experiment. Oral CBD has failed three controlled trials, while the limited evidence for application through the skin is more encouraging.
Keep taking what you’ve been prescribed. Particularly with inflammatory arthritis.
Tell your rheumatologist or GP. CBD interacts with a number of medications, and people with arthritis often take several — see our guide to CBD and drug interactions.
Judge it on function, not just pain. Grip strength, stiffness in the morning, whether you can do something you couldn’t last month. Those are more informative than a pain score.
Give it a defined trial. A few weeks at a consistent dose, then an honest assessment. No effective oral dose has been established: trials using 20–45 mg daily have been negative, but so has one using 600 mg. Increasing the dose isn’t an evidence-based solution. With a topical, more product doesn’t necessarily mean more CBD reaches the joint — formulation and skin penetration matter.
Where this leaves it
CBD taken by mouth has now failed three controlled arthritis trials, at doses from 20 to 600 mg daily. That’s worth knowing before spending money on capsules or oil specifically for arthritis.
Application through the skin remains a more open question. One small randomised trial was positive, and an uncontrolled transdermal study reported improvements in pain and grip strength. Neither proves ordinary CBD creams work, but they’re a reasonable basis for better trials. THC-containing cannabis medicines may offer broader symptom relief, though the arthritis-specific evidence is limited.
For someone who wants to experiment, a verified topical on a specific painful joint is a reasonable place to start. Set a clear goal, keep proven treatment in place, and stop if it produces no worthwhile improvement.
None of this is medical advice.
For more, see our guide to CBD for pain, our guide to what the research actually shows, or browse Pain & Recovery.
References
- Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–2451. doi:10.1097/j.pain.0000000000001052
- Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain. 2016;20(6):936–948. doi:10.1002/ejp.818
- Pramhas S, Thalhammer T, Terner S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. The Lancet Regional Health – Europe. 2023;35:100777. doi:10.1016/j.lanepe.2023.100777
- Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206–1214. doi:10.1097/j.pain.0000000000002466
- Mojoli A, Haider O, Fakih Y, et al. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial — CANOA. Frontiers in Pharmacology. 2025;16:1657065. doi:10.3389/fphar.2025.1657065
- Heineman JT, Forster GL, Stephens KL, et al. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. Journal of Hand Surgery (American Volume). 2022;47(7):611–620. doi:10.1016/j.jhsa.2022.03.002
- Bawa Z, Lewis D, Gavin PD, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Scientific Reports. 2024;14:11792. doi:10.1038/s41598-024-62428-x
- Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases. Schmerz. 2016;30(1):47–61. doi:10.1007/s00482-015-0084-3
- Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45(1):50–52. doi:10.1093/rheumatology/kei183
- Xiao ATY, Turk T, Deol K, et al. Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review. Clinical Rheumatology. 2024;43:2375–2390. doi:10.1007/s10067-024-07001-7
- Arthritis Foundation. Patients tell us about CBD use. Survey of approximately 2,600 people, 2019. arthritis.org
About this article
Substantially rewritten in August 2026. This update adds the randomised trials published since, separates the oral evidence from the topical evidence, and distinguishes osteoarthritis from rheumatoid arthritis. With earlier reporting by Asia Mayfield.
